A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
In a study published in Nature Communications on May 14, a research team led by scientists from University College London (UCL) found a new target for the treatment of hepatitis B. The targeted therapy of HBV can not only inhibit the replication of HBV, but also stimulate T cell activity against HBV-infected liver cells. The researchers said that this target may bring a highly effective and innovative therapy for the treatment of chronic HBV infection and liver cancer.doi:10.5281/zenodo.4925657 fatcat:tjq6y2ywjjaqvhiyjzjpzk75p4